• Molecular NameLevosimendan
  • SynonymLevosimedan
  • Weight280.291
  • Drugbank_IDDB00922
  • ACS_NO141505-33-1
  • Show 2D model
  • LogP (experiment)N/A
  • LogP (predicted, AB/LogP v2.0)2.56
  • pka6.3
  • LogD (pH=7, predicted)2.56
  • Solubility (experiment)Soluble
  • LogS (predicted, ACD/Labs)(ph=7)-2.79
  • LogSw (predicted, AB/LogsW2.0)0.42
  • Sw (mg/ml) (predicted, ACD/Labs)0.04
  • No.of HBond Donors2
  • No.of HBond Acceptors7
  • No.of Rotatable Bonds5
  • TPSA113.43
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA calcium sensitiser used in the management of acutely decompensated congestive heart failure.
  • Absorption_value90.0
  • Absorption (description)Levosimendan is rapidly absorbed after administration and distributed quickly around the body. The extent of absorption increases in the fasted state and the degree of absorption may be affected by the formulation of the drug used.
  • Caco_2N/A
  • Bioavailability85.0
  • Protein binding96.5
  • Volume of distribution (VD)21.9 L (healthy); 19.5 L (patients with mild congestive heart failure). Also reported as 14.7 L.
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIt is completely metabolised with negligible amounts of the unchanged drug being detected in urine and faeces. The main metabolites are conjugates of the glutathione pathway and cyclic, N-acetylated cysteine or cysteinylglycine derivatives. These metabolites are biologically inactive and are slowly formed.
  • Half life0.96 h (healthy individuals); 1.03 h (patients with mild congestive heart failure).
  • Excretionrenal
  • Urinary ExcretionN/A
  • Clerance359 ml/min (healthy); 296 ml/min (patients with mild congestive heart failure). Also reported as 246 mL/min.
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A